BUDGET IMPACT OF ADDING DELAYED-RELEASE DIMETHYL FUMARATE TO THE FORMULARY FOR THE TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS

被引：0
|
作者：
Mauskopf, J. A. [1 ]
Fay, M. [2 ]
Iyer, R. [3 ]
Livingston, T. [2 ]
机构：
[1] RTI Hlth Solut, Res Triangle Pk, NC USA
[2] Biogen Idec Inc, Weston, MA USA
[3] Biogen Idec Inc, Cambridge, MA USA
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 03期
关键词：
D O I：
10.1016/j.jval.2014.03.341
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND10
引用
收藏
页码：A58 / A58
页数：1
相关论文
共 50 条
  • [1] Budget impact analysis of delayed-release dimethyl-fumarate in the treatment of relapsing-remitting multiple sclerosis in Italy
    Furneri, Gianluca
    Marchesi, Chiara
    Santoni, Laura
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2016, 17 (01) : 29 - 39
  • [2] Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States
    Mauskopf, Josephine
    Fay, Monica
    Iyer, Ravi
    Sarda, Sujata
    Livingston, Terrie
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (04) : 432 - 442
  • [3] The budget impact of introducing delayed-release dimethyl fumarate for treatment of relapse-remitting multiple sclerosis in Canada
    Dorman, Emily
    Kansal, Anuraag R.
    Sarda, Sujata
    JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (12) : 1085 - 1091
  • [4] BUDGET IMPACT OF ADDING PEGINTERFERON BETA-1A TO THE FORMULARY FOR THE TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS
    Mauskopf, J. A.
    Graham, J.
    Fay-Azhar, M.
    Kinter, E.
    VALUE IN HEALTH, 2015, 18 (03) : A280 - A281
  • [5] COST-EFFECTIVENESS ANALYSIS OF DELAYED-RELEASE DIMETHYL FUMARATE FOR THE TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS IN SPAIN
    Gasche, D.
    Restovic, G.
    Casado, V
    Ramirez-Boix, P.
    Martinez Lopez, J.
    VALUE IN HEALTH, 2015, 18 (07) : A755 - A755
  • [6] The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada
    Su, Wenqing
    Kansal, Anuraag
    Vicente, Colin
    Deniz, Baris
    Sarda, Sujata
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (07) : 718 - 727
  • [7] Safety and Efficacy of Delayed-Release Dimethyl Fumarate in Pediatric Patients With Relapsing Multiple Sclerosis (FOCUS)
    Alroughani, Raed
    Das, Rajiv
    Penner, Natasha
    Pultz, Joe
    Taylor, Catherine
    Eraly, Satish
    PEDIATRIC NEUROLOGY, 2018, 83 : 19 - 24
  • [8] BUDGET IMPACT ANALYSIS OF DELAYED-RELEASE DIMETHYLFUMARATE IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY
    Furneri, G.
    Marchesi, C.
    Santoni, L.
    VALUE IN HEALTH, 2015, 18 (07) : A700 - A701
  • [9] Delayed-Release Dimethyl Fumarate Safety and Efficacy in Pediatric Patients With Relapsing-Remitting Multiple Sclerosis
    Alroughani, Raed
    Huppke, Peter
    Mazurkiewicz-Beldzinska, Maria
    Blaschek, Astrid
    Valis, Martin
    Aaen, Gregory
    Pultz, Joe
    Peng, Xiaomei
    Beynon, Vanessa
    FRONTIERS IN NEUROLOGY, 2021, 11
  • [10] COST-EFFECTIVENESS ANALYSIS OF DELAYED-RELEASE DIMETHYL-FUMARATE IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY
    Fumeri, G.
    Santoni, L.
    Marchesi, C.
    Iannazzo, S.
    Cortesi, R.
    Piacentini, P.
    Caputi, A.
    Mantovani, L. G.
    VALUE IN HEALTH, 2015, 18 (07) : A697 - A697
12345